Cavis Technologies AB

Cavis Technologies AB is a Swedish-based med-tech startup that aims to revolutionize the diagnosis and treatment of coronary artery disease. With the slogan "Providing a new level of precision in assessment of coronary artery disease," the company has focused on developing, producing, and supplying innovative invasive cardiology care units since its founding in 2015. Their flagship product, Wirecath, addresses the critical need for precise measurements in pressure guide wires, aiming to eliminate hydrostatic pressure errors encountered in traditional alternatives. The company's groundbreaking technology has attracted attention and investment, with Sciety leading a €900.00K Seed Round investment in Cavis Technologies AB on 01 February 2020. This investment reflects the growing confidence in the company's potential to transform the Health Care and Pharmaceutical industries with its innovative solutions. Cavis Technologies AB's dedication to precision and overcoming existing challenges in cardiovascular disease diagnosis and treatment underscores its potential for impactful disruption within the med-tech sector.